Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 909 | 159 | 742 |
| Samples | 731 | 132 | 591 |
| Peptides | 529 | 90 | 461 |
Function
PLG · Plasminogen
The plasminogen protein encoded by this gene is a serine protease that circulates in blood plasma as an inactive zymogen and is converted to the active protease, plasmin, by several plasminogen activators such as tissue plasminogen activator (tPA), urokinase plasminogen activator (uPA), kallikrein, and factor XII (Hageman factor). The conversion of plasminogen to plasmin involves the cleavage of the peptide bond between Arg-561 and Val-562. Plasmin cleavage also releases the angiostatin protein which inhibits angiogenesis. Plasmin degrades many blood plasma proteins, including fibrin-containing blood clots. As a serine protease, plasmin cleaves many products in addition to fibrin such as fibronectin, thrombospondin, laminin, and von Willebrand factor. Plasmin is inactivated by proteins such as alpha-2-macroglobulin and alpha-2-antiplasmin in addition to inhibitors of the various plasminogen activators. Plasminogen also interacts with plasminogen receptors which results in the retention of plasmin on cell surfaces and in plasmin-induced cell signaling. The localization of plasminogen on cell surfaces plays a role in the degradation of extracellular matrices, cell migration, inflamation, wound healing, oncogenesis, metastasis, myogenesis, muscle regeneration, neurite outgrowth, and fibrinolysis. This protein may also play a role in acute respiratory distress syndrome (ARDS) which, in part, is caused by enhanced clot formation and the suppression of fibrinolysis. Compared to other mammals, the cluster of plasminogen-like genes to which this gene belongs has been rearranged in catarrhine primates. [provided by RefSeq, May 2020].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 522 amino-acid changes on canonical ENST00000308192 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PLG · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PLG – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 22/210 10% | 130/1899 7% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 27/612 4% |
| Non-Small Cell Lung Carcinoma | 29/304 10% | 46/1390 3% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Hodgkins Lymphoma | 1/16 6% | 3/122 2% |
| Other Solid Cancers | 1/94 1% | 42/1515 3% |
| Neuroendocrine Tumour | 13/154 8% | 4/577 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 18/810 2% |
| Colorectal Carcinoma | 10/143 7% | 68/3239 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 3/133 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Gastric Carcinoma | 6/74 8% | 32/1809 2% |
| Mesothelioma | 2/62 3% | 2/165 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 12/752 2% |
| Bladder Carcinoma | 0/58 0% | 13/956 1% |
| Plasma Cell Myeloma | 0/44 0% | 4/305 1% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Other Sarcomas | 2/69 3% | 6/699 1% |
| Esophageal Carcinoma | 0/23 0% | 8/769 1% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 23/2550 1% |
| Osteosarcoma | 2/45 4% | 0/166 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 14/1592 1% |
| Head and Neck Carcinoma | 1/85 1% | 14/1574 1% |
| Hepatocellular Carcinoma | 0/46 0% | 20/2210 1% |
| Glioma | 2/52 4% | 17/2127 1% |
| Medulloblastoma | 0/0 0% | 3/450 1% |
| B-Cell Non-Hodgkins Lymphoma | 7/88 8% | 10/2534 0% |
Mutation Distribution
Where PLG is mutated · all tissues, split by cell line vs tissue
How many mutations in PLG were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 48 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 909 mutations in PLG
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|